MaxCyte Raises 2026 Revenue Guidance Following Strong Preliminary Q3 Results

Key Facts

1MaxCyte reported preliminary third-quarter 2026 revenue and increased its full-year 2026 revenue guidance.

2The company will host its third-quarter 2026 earnings conference call on November 10, 2026.

MaxCyte reported preliminary third-quarter 2026 revenue and increased its full-year 2026 revenue guidance. According to a statement released via GlobeNewswire, the company's revenue for the third quarter and the first half of the second semester exceeded previous expectations, leading to an upward revision of its financial outlook.

MXCT closed at $0.9643 on October 13, 2026, with the session seeing a high of $1.01 and a low of $0.93605. The company now expects its core business revenue to grow by approximately 15% year-over-year in the second half of 2026, as noted by President and CEO Maher Masoud.

The company is scheduled to host its formal third-quarter 2026 earnings conference call to discuss these financial results on November 10, 2026.